Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Friday, Keefe, Bruyette & Woods updated their stance on Palomar Holdings (NASDAQ:PLMR), increasing the price target to $205 from the previous $195 while maintaining an Outperform rating on the stock. The revision follows Palomar’s announcement of its updated financial outlook for fiscal year 2025, which now projects adjusted net income in the range of $195-205 million, an increase from the prior guidance of $186-200 million.
This optimistic adjustment comes on the heels of Palomar completing its June 1 reinsurance renewals, which resulted in a 10% decrease in risk-adjusted reinsurance rates. Additionally, the company has secured a lower hurricane retention and has added $455 million of extra earthquake limit. These strategic moves are expected to have a positive impact on the stock’s performance, which has already demonstrated strength with a 92.86% return over the past year. According to InvestingPro, 4 analysts have recently revised their earnings estimates upward for the upcoming period.
Analysts at Keefe, Bruyette & Woods have expressed a positive outlook, anticipating that Palomar shares will experience an upward movement following the announcement of the raised financial guidance. In light of these developments, the firm has also revised its earnings per share (EPS) estimates for Palomar, increasing them to $6.95 for 2025 and $8.40 for 2026, up from the earlier estimates of $6.75 and $8.25, respectively. Furthermore, they have introduced an initial EPS forecast of $9.70 for 2027.
The price target adjustment to $205 is based on a discounted cash flow (DCF) analysis. Keefe, Bruyette & Woods’ analysts have cited the expected improvements in net-to-gross written and earned premium ratios and slightly reduced catastrophe loads as contributing factors to the enhanced financial projections for Palomar Holdings.
In other recent news, Palomar Holdings reported a significant earnings beat for the first quarter of 2025, with adjusted earnings per share (EPS) reaching $1.87, surpassing the forecasted $1.62. The company achieved a 20% increase in gross written premiums, amounting to $442.2 million, although revenue slightly missed expectations. Following this performance, Keefe, Bruyette & Woods raised its price target for Palomar to $195, maintaining an Outperform rating, while Truist Securities increased its target to $188, upholding a Buy rating. Both firms cited Palomar’s strong earnings potential and robust growth as reasons for their positive outlooks. Analysts at KBW and Truist have revised their EPS estimates for 2025 and 2026 upwards, anticipating continued growth driven by factors such as lower reinsurance costs and strategic initiatives. Palomar’s strategic expansion in crop insurance and casualty lines contributed to an 85% increase in adjusted net income, highlighting the company’s effective cost management and growth in high-margin segments. The company also raised its full-year 2025 adjusted net income guidance, reflecting optimism about its growth trajectory. These developments indicate a strong start to the year for Palomar Holdings, with analysts expressing confidence in the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.